Amgen, Inc. (AMGN)
344.72
+7.12
(+2.11%)
USD |
NASDAQ |
Jun 22, 16:00
344.00
-0.72
(-0.21%)
After-Hours: 20:00
Amgen Cash from Operations (TTM) : 10.76B for March 31, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 10.76B |
| December 31, 2025 | 9.958B |
| September 30, 2025 | 13.13B |
| June 30, 2025 | 12.01B |
| March 31, 2025 | 12.19B |
| December 31, 2024 | 11.49B |
| September 30, 2024 | 7.257B |
| June 30, 2024 | 6.446B |
| March 31, 2024 | 8.096B |
| December 31, 2023 | 8.471B |
| September 30, 2023 | 10.58B |
| June 30, 2023 | 10.80B |
| March 31, 2023 | 8.621B |
| December 31, 2022 | 9.721B |
| September 30, 2022 | 9.88B |
| June 30, 2022 | 9.32B |
| March 31, 2022 | 9.321B |
| December 31, 2021 | 9.261B |
| September 30, 2021 | 8.606B |
| June 30, 2021 | 9.556B |
| March 31, 2021 | 10.47B |
| December 31, 2020 | 10.50B |
| September 30, 2020 | 10.86B |
| June 30, 2020 | 10.87B |
| March 31, 2020 | 9.439B |
| Date | Value |
|---|---|
| December 31, 2019 | 9.15B |
| September 30, 2019 | 9.83B |
| June 30, 2019 | 9.726B |
| March 31, 2019 | 10.41B |
| December 31, 2018 | 11.30B |
| September 30, 2018 | 11.11B |
| June 30, 2018 | 11.30B |
| March 31, 2018 | 11.52B |
| December 31, 2017 | 11.18B |
| September 30, 2017 | 11.26B |
| June 30, 2017 | 10.47B |
| March 31, 2017 | 10.82B |
| December 31, 2016 | 10.35B |
| September 30, 2016 | 9.314B |
| June 30, 2016 | 9.526B |
| March 31, 2016 | 9.663B |
| December 31, 2015 | 9.077B |
| September 30, 2015 | 9.462B |
| June 30, 2015 | 9.329B |
| March 31, 2015 | 8.742B |
| December 31, 2014 | 8.555B |
| September 30, 2014 | 7.945B |
| June 30, 2014 | 7.011B |
| March 31, 2014 | 6.384B |
| December 31, 2013 | 6.291B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Gilead Sciences, Inc. | 10.81B |
| Regeneron Pharmaceuticals, Inc. | 5.013B |
| AbbVie, Inc. | 21.22B |
| Viridian Therapeutics, Inc. | -303.87M |
| Biogen, Inc. | 2.591B |